Group 1: AbbVie Overview - AbbVie is one of the largest pharmaceutical companies globally, particularly recognized for its immunology portfolio, including best-selling therapies like Humira, Skyrizi, and Rinvoq [1][3] - AbbVie has a strong revenue generation capability due to its established product lineup, with Skyrizi and Rinvoq being significant growth drivers that will not lose patent exclusivity until the next decade [4] - AbbVie is noted for its consistent dividend payouts, being classified as a Dividend King, which enhances its appeal as a reliable income stock [4] Group 2: Abivax Overview - Abivax is a clinical-stage biotech company currently without revenue and unprofitable, but it has a promising candidate, obefazimod, in development for ulcerative colitis [5] - Unlike AbbVie's immunosuppressants, obefazimod takes a different approach that may be equally effective without compromising the immune system [5] - The potential of Abivax's obefazimod presents significant upside for investors looking for high-risk, high-reward opportunities in the biotech sector [5]

Core Insights - Upcoming Medicare coverage for obesity drugs is expected to significantly boost the rollout of Eli Lilly's experimental weight loss pill, orforglipron [1] - Eli Lilly anticipates Medicare coverage to begin immediately after the launch of orforglipron, which could alter the competitive landscape [1] - The early success of Novo Nordisk's GLP-1 obesity pill, Wegovy, indicates a strong market demand, with many early adopters being new to GLP-1 treatments [2] Company Strategy - Eli Lilly is preparing for a "full launch" of orforglipron in the second quarter, coinciding with the introduction of Medicare coverage for obesity medications [2] - The company is confident in its pill's competitive ability against existing treatments, particularly in light of the new Medicare coverage [2] Market Dynamics - The current market shows that many patients are paying out-of-pocket for Novo Nordisk's Wegovy, which has seen a strong start despite inconsistent insurance coverage [1] - The introduction of Medicare coverage for obesity drugs is part of drug pricing deals made with the Trump administration, which could further influence market dynamics [2]

Core Insights - The article emphasizes the value of in-depth analysis in the Biotech sector, highlighting the services offered by Biotech Analysis Central, which includes a model portfolio and extensive research articles [1][2]. Group 1: Company Overview - Biotech Analysis Central provides a subscription service that includes over 600 articles focused on Biotech investing, aimed at helping investors make informed decisions [2]. - The service offers a model portfolio consisting of more than 10 small and mid-cap stocks, each accompanied by detailed analysis [2]. Group 2: Subscription Details - The monthly subscription fee for Biotech Analysis Central is $49, with a yearly plan available at a discounted rate of $399, representing a 33.50% savings [1].

Core Viewpoint - Corcept Therapeutics faces significant setbacks regarding its proposed treatment for hypercortisolism, relacorilant, following warnings from the FDA not to submit its drug application, leading to a sharp decline in share price [1][2]. Company Developments - On January 30, 2026, Corcept shares dropped by $7.81, or 17%, after reports of FDA warnings against submitting the drug application [1]. - The company's market capitalization has decreased by $3.2 billion since December 30, 2025, following the receipt of a complete response letter (CRL) from the FDA [4]. FDA Communications - The FDA had previously issued a CRL indicating that it could not arrive at a favorable benefit-risk assessment for relacorilant without additional evidence of effectiveness [3]. - A corrected CRL dated January 28 revealed that the FDA had warned Corcept on multiple occasions about significant review issues if the application was submitted [3]. Investor Concerns - Hagens Berman, a law firm, is investigating whether Corcept misled investors regarding relacorilant's efficacy and the company's communications with the FDA [2][4]. - The firm is also analyzing if Corcept overstated its commercial and growth prospects for the hypercortisolism business, which was projected to grow from $3 billion to $5 billion in annual revenues within three to five years [3].

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Sun Pharmaceuticals Ltd., Central Depository Services Ltd., IDFC First Bank Ltd., and Delhivery Ltd. are among the companies that will announce their third quarter results on Saturday, Jan 31. Here are the analysts' consensus estimates compiled by Bloomberg:Sun Pharma's consolidated Q3 estimates indicate growth on revenue and profit, with softer margins year‑on‑year. Revenue is projected at Rs 14,792 crore versus Rs 13,675 crore, up 8% YoY. Ebitda is estimated at Rs 4,163 crore compared with Rs 4,009 crore, ...

Core Viewpoint - Corcept Therapeutics is under investigation for potential securities law violations following a disappointing response from the FDA regarding its drug application for relacorilant, leading to a significant drop in its stock price [1][2][3]. Investigation Details - On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for relacorilant, which is intended for treating hypertension secondary to hypercortisolism. The company expressed surprise and disappointment at this outcome [2]. - Following the announcement, Corcept's stock price fell by $35.40, closing at $34.80 per share on the same day [2]. - On January 30, 2026, it was reported that Corcept's shares fell an additional 16% after a corrected CRL indicated that the FDA had previously warned the company against submitting its drug application [3]. Company Background - Corcept Therapeutics is based in Redwood City, California, and focuses on developing treatments for patients with severe metabolic and psychiatric disorders [1]. - Berman Tabacco, the law firm investigating Corcept, has a history of prosecuting securities cases on behalf of investors and has been recognized for its work in this field [4].

Core Insights - Takeda Pharmaceutical Company Limited (TAK) was previously discussed in May, indicating a challenging outlook for 2025 as the stock was underperforming [1] Company Overview - The company is currently facing difficulties, with expectations of a tough fiscal year ahead [1] Analyst Background - The analysis is conducted by an experienced individual with over 20 years in foreign policy research and 25 years in investment analysis, focusing on deep-discount value plays [1]

Core Insights - Takeda Pharmaceutical Company Limited (TAK) was previously discussed in May, indicating a challenging outlook for 2025 [1] Company Overview - The stock of Takeda was significantly undervalued at the time of the last analysis, suggesting potential for recovery [1] Analyst Background - The analysis is conducted by an experienced analyst with over 20 years in foreign policy research and 25 years in investment analysis, focusing on value plays [1]

Core Insights - Kyowa Kirin Co., Ltd. and Amgen Inc. have terminated their collaboration on the development and commercialization of rocatinlimab, with Kyowa Kirin regaining control over the global program [1][2] Group 1: Collaboration Details - The collaboration was initiated in June 2021, focusing on KHK4083, a Phase 3-ready anti-OX40 monoclonal antibody for atopic dermatitis and other autoimmune diseases [2] - Amgen made an upfront payment of $400 million and Kyowa Kirin was eligible for milestone payments up to $850 million [3] Group 2: Clinical Trial Insights - Preliminary topline results from the ASCEND study, evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis, were released in September 2025 [3] - The incidence of gastrointestinal ulceration events with rocatinlimab is reported to be less than 1 per 100 patient-years across the Phase 3 ROCKET program [4] Group 3: Analyst Commentary - The decision to terminate the agreement was unexpected, occurring after a broad Phase 3 program and just before a planned regulatory submission [5] - Recent updates in the OX40 development landscape have diminished enthusiasm for the target, with Phase 3 efficacy falling short of Phase II benchmarks [5] - Concerns regarding rocatinlimab's toxicity profile, including high rates of pyrexia and chills, may pose commercial challenges [6] Group 4: Investor Sentiment - The discontinuation of rocatinlimab is not expected to impact the investment thesis for Amgen, given low investor expectations for therapies targeting the OX40 pathway [7] - Amgen's CEO shared findings from part 2 of the Phase 2 study of MariTide, an investigational obesity treatment, at a J.P. Morgan Healthcare Conference [7] - Amgen acquired Dark Blue Therapeutics for up to $840 million, focusing on precision oncology medicines [7] Group 5: Stock Performance - As of the publication date, Amgen's stock was down 0.81% at $340.17 [8]